Lunai Bioworks (RENB) Stock Price, News & Analysis

Company Overview

Renovaro Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company's product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV. It also develops RENB-DC-11, an allogeneic dendritic cell therapeutic vaccine for pancreatic cancer; RENB-DC-12-XX, an allogeneic dendritic cell therapeutic vaccine for other solid tumors; and RENB-HV-21 for treating HIV with allogeneic natural killer (NK) and gamma delta T-cells. It has strategic partnerships with the University of California, Fred Hutchinson Cancer Research Center, and Caring Cross. The company was formerly known as Renovaro Biosciences Inc. and changed its name to Renovaro Inc. in February 2024. Renovaro Inc. is headquartered in Los Angeles, California.

Key Stats

• Today's Range: $1.13 to $1.43
• 50-Day Range: $1.30 to $2.38
• 52-Week Range: $0.12 to $1.43
• Volume: 880,400 shs
• Average Volume: 2.93 million shs
• Market Capitalization: $250.24 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

RENB Stock Analysis - Frequently Asked Questions

How were Lunai Bioworks' earnings last quarter?

Lunai Bioworks Inc. (NASDAQ:RENB) announced its quarterly earnings results on Wednesday, February, 19th. The company reported ($0.20) earnings per share for the quarter.

When did Lunai Bioworks' stock split?

Lunai Bioworks's stock reverse split on Monday, September 29th 2025.The 1-10 reverse split was announced on Wednesday, September 24th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Friday, September 26th 2025. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

When did Lunai Bioworks IPO?

Lunai Bioworks (RENB) raised $12 million in an IPO on the week of December 10th 2018. The company issued 2,400,000 shares at a price of $5.00 per share.

What other stocks do shareholders of Lunai Bioworks own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Lunai Bioworks investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE), Arista Networks (ANET), e.l.f. Beauty (ELF) and ServiceNow (NOW).

Company Calendar

• Last Earnings: 2/19/2025
• Today: 5/07/2026
• AGM 2026: 5/08/2026
• Fiscal Year End: 6/30/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:RENB
• CIK: 1527728
• Web: www.enochianbio.com
• Phone: 305-918-1980
• Fax: N/A
• Employees: 20
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($0.77)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$88.43 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -60.38%
• Return on Assets: -47.04%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.13
• Quick Ratio: 0.13

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.89 per share
• Price / Book: 1.73

Miscellaneous

• Outstanding Shares: 162,390,000
• Free Float: 171,258,000
• Market Cap: $250.24 million
• Optionable: Optionable
• Beta: 0.54